A single-dose influenza a (H5N1) vaccine safe and immunogenic in adult and elderly patients: An approach to pandemic vaccine development

Journal of Virology

Volumn 84, Issue 3, 2010, Pages 1237-1242

  Vajo, Zoltan ^f   Wood, John ^b   Kosa, Lajos ^a   Szilvasy, Istvan ^d   Paragh, Gyorgy ^g   Pauliny, Zsuzsanna ^c   Bartha, Kálmán ^c   Visontay, Ildiko ^c   Kis, Agnes ^e   Jankovics, Istvan ^c  

^a National Center for Allergy and Immunology   (Hungary)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^d State Health Center   (Hungary)

^e Orszagos Gyogyszereszeti Intezet   (Hungary)

^f UNIVERSITY OF DEBRECEN   (Hungary)

^g National Internal Medicine Supervisor Office   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEVER; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE WARMTH; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; PANDEMIC; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS;

ADULT; AGED; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; REFERENCE VALUES;

INFLUENZA A VIRUS; SUIDAE;

EID: 73949156426     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01894-09     Document Type: Article

References (33)

1. Bresson, J. L., C. Perronne, O. Launay, C. Gerdil, M. Saville, J. Wood, K. Höschler, and M. C. Zambon. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664.
2. Dennis, C. 2006. Flu-vaccine makers toil to boost supply. Nature 440:1099.
3. European Parliament. 28 November 2001. EC guide to good manufacturing practice (GMP), vol. 4. Based upon directive 2001/83/EC of the European Parliament and the Council of 6 November 2001 relating to medicinal products for human use, p. 67-128. European Parliament, Strasbourg, France.
4. Ehrlich, H. J., M. Müller, H. M. Oh, P. A. Tambyah, C. Joukhadar, E. Montomoli, D. Fisher, G. Berezuk, S. Fritsch, A. Löw-Baselli, N. Vartian, R. Bobrovsky, B. G. Pavlova, E. M. Pöllabauer, O. Kistner, and P. N. Barrett. 2008. Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358:2573-2584.
5. European Committee for Proprietary Medicinal Products. 12 March 1997. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
6. European Committee for Proprietary Medicinal Products. 5 April 2004. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
7. European Directorate for the Quality of Medicines. 2007. European pharmacopeia, p.3406-3407. European Directorate for the Quality of Medicines, Strasbourg, France.
8. European Medicines Agency. 2005. Guideline on adjuvants in vaccines for human use (CHMP/VEG/134716/2004). European Medicines Agency, London, United Kingdom. http://www.emea.europa.eu/pdfs/human/vwp/13471604en.pdf.
9. Fazekas, G., R. Martosne-Mendi, I. Jankovics, I. Szilvasy, and Z. Vajo. 2009. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin. Vaccine Immunol. 16:437-443.
10. Giesecke, J., C. Sellwood, and J. Van-Tam. 2007. Expert advisory groups on human H5N1 vaccines, p.47. European Centre for Disease Control and Prevention, Stockholm, Sweden.
11. Kendal, A. P., M. S. Pereira, and J. J. Skehel (ed.). 1982. Concepts and procedures for laboratory based influenza surveillance. Centers for Disease Control, Atlanta, GA.
12. Klimov, A., and N. Cox. 2003. Serologic diagnosis of influenza virus infections by hemagglutination inhibition, p. 7.1-7.5. Centers for Disease Control, Atlanta, GA.
13. Leroux-Roels, I., A. Borkowski, T. Vanwolleghem, M. Dramé, F. Clement, E. Hons, J. M. Devaster, and G. Leroux-Roels. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589.
14. Lin, J., J. Zhang, X. Dong, H. Fang, J. Chen, N. Su, Q. Gao, Z. Zhang, Y. Liu, Z. Wang, M. Yang, R. Sun, C. Li, S. Lin, M. Ji, Y. Liu, X. Wang, J. Wood, Z. Feng, Y. Wang, and W. Yin. 2006. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368:991-997.
15. National Institute of Pharmacy. 1995. License number OGYI-T-8998/01. National Institute of Pharmacy, Budapest, Hungary.
16. Nolan, T. M., P. C. Richmond, M. V. Skeljo, G. Pearce, G. Hartel, N. T. Formica, K. Höschler, J. Bennet, D. Ryan, K. Papanaoum, R. L. Basser, and M. C. Zambon. 2008. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26:4160-4167.
17. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
18. Rowe, T., R. A. Abernathy, J. Hu-Primmer, W. W. Thompson, X. Lu, W. Lim, K. Fukuda, N. J. Cox, and J. M. Katz. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37:937-943.
19. Stephenson, I., K. G. Nicholson, J. M. Wood, M. C. Zambon, and J. M. Katz. 2004. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect. Dis. 4:499-509.
20. Takatsy, G. 1952. Purified precipitated virus obtained by a new simple method. Acta Med. Acad. Sci. Hung. 3:185-191.
21. Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, and M. Wolff. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
22. Ungchusak, K., P. Auewarakul, S. F. Dowell, R. Kitphati, W. Auwanit, P. Puthavathana, M. Uiprasertkul, K. Boonnak, C. Pittayawonganon, N. J. Cox, S. R. Zaki, P. Thawatsupha, M. Chittaganpitch, R. Khontong, J. M. Simmerman, and S. Chunsutthiwat. 2005. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352:333-340.
23. U.S. Food and Drug Administration. 2007. Draft guidance on clinical data needed to support the licensure of pandemic influenza vaccines. U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/cber/ gdlns/panfluvac.htm.
24. Vajo, Z., L. Kosa, I. Visontay, M. Jankovics, and I. Jankovics. 2007. Inactivated whole virus influenza A (H5N1) vaccine. Emerg. Infect. Dis. 13:807-808.
25. Vajo, Z., L. Kosa, I. Szilvasy, Z. Pauliny, K. Bartha, I. Visontay, M. Jankovics, A. Kis, and I. Jankovics. 2008. Yearly licensing studies from 1997-2007 of the inactivated whole virus seasonal influenza vaccine Fluval-a useful approach to pandemic vaccine development even in less well developed countries? Influenza Other Respir. Viruses 2:211-218.
26. Vajo, Z., L. Kosa, I. Szilvasy, Z. Pauliny, K. Bartha, I. Visontay, A. Kis, I. Tarjan, N. Rozsa, and I. Jankovics. 2008. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr. Infect. Dis. J. 27:1052-1056.
27. Voordouw, A. C., M. C. Sturkenboom, J. P. Dieleman, T. Stijnen, D. J. Smith, J. van der Lei, and B. H. Stricker. 2004. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 292:2089-2095.
28. Walls, H. H., M. W. Harmon, J. J. Slagle, C. Stocksdale, and A. P. Kendal. 1986. Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses. J. Clin. Microbiol. 23:240-245.
29. Wood, J. M., G. C. Schild, R. W. Newman, and V. Seagroatt. 1977. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5:237-247.
30. World Health Organization. 13 June 2009, accession date. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/ disease/avian-influenza/country/cases-table-2009-06-02/en/index.html.
31. World Health Organization. 2009. Tables on the clinical trials of pandemic influenza prototype vaccines. World Health Organization, Geneva, Switzerland. http://www.who.int/vaccine-research/diseases/influenza/flu-trials- tables/en/index.html.
32. World Health Organization. 13 June 2007, posting date. WHO and manufacturers move ahead with plans for H5N1 influenza global vaccine stockpile. World Health Organization, Geneva, Switzerland. www.who.int/mediacentre/news/ statements/2007/s14/en/index.html.
33. Yang, Y., M. E. Halloran, J. D. Sugimoto, and I. M. Longini, Jr. 2007. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg. Infect. Dis. 13:1348-1353.